Intravesical BCG vs GEMDOCE in NMIBC (BRIDGE)
The study hypothesis is that BCG na茂ve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with鈥�
- Investigator
- Padraic O'Malley
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
Addition of Pembrolizumab to Usual Intravesical Gemcitabine for Treatment of BCG-Unresponsive NMIBC
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as鈥�
- Investigator
- Paul L Crispen
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
BL infusion trial
The study plans to randomize a total of 240 patients infected with Gram-negative bacterial pneumonia to receive beta-lactam (meropenem, cefepime, or piperacillin/tazobactam) continuous or intermittent infusion and collect baseline and regular鈥�
- Status
- Accepting Candidates
- Ages
- 18 Years - 100 Years
- Sexes
- All